Florida Republicans Propose Six-Week Abortion Ban, Further Narrowing Abortion Access
Florida Republicans introduced a bill to ban abortion after six weeks of pregnancy, offering exemptions for victims of rape and incest cases.
Canadian Agency For Drugs And Technologies In Health Recommends Reimbursement For BioCryst’s ORLADEYO For The Routine Prevention Of Attacks In Hereditary Angioedema Patients In Canada
BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced that the Canadian Agency for Drugs and Technologies in Health (CADTH) Canadian Drug Expert Committee (CDEC) has issued a positive recommendation for
CEL-SCI’s Lead Head & Neck Cancer Candidate Shows 43% Survival Extension
CEL-SCI Corporation (NASDAQ:CVM) reported new data from its pivotal Phase 3 study of Multikine (Leukocyte Interleukin) in newly diagnosed locally advanced…
FDA Removes Regulatory Overhang From Inhibikase Therapeutics Parkinson, Atrophy Program
The FDA lifted the full Clinical Hold on Inhibikase Therapeutics Inc’s (NASDAQ:IKT) IkT-148009, the company’s c-Abl inhibitor, in Multiple System…
Enanta Pharmaceuticals To Present New Data For EDP-235, Its 3CL Protease Inhibitor, In Development As An Oral, Once-Daily Treatment For COVID-19, At The 36th International Conference On Antiviral Research
Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA), a clinical stage biotechnology company dedicated to creating small molecule drugs for viral infections, today announced that data for EDP-235, its lead 3CL protease
AIM ImmunoTech Announces Publication Of New Analysis Of The Mechanism Of Action Of Ampligen As A Potential Prophylactic Therapy Against Ebola Virus Disease
AIM ImmunoTech Inc. (NYSE:AIM) ("AIM" or the "Company"), an immuno-pharma company focused on the research and development of therapeutics to treat multiple types of cancers, immune disorders, and
Mesoblast’s Lead Drug Candidate Goes Under FDA Priority Review For Bone Marrow Transplant Complications In Kids
Mesoblast Ltd (NASDAQ:MESO) rallied after the FDA agreed to review the company’s lead drug candidate, remestemcel-L, on a priority basis, more…
Sage Therapeutics & Biogen Reveal FDA Does Not Currently Plan To Convene Advisory Committee Meeting To Discuss NDA For Zuranolone In Treatment Of Major Depressive Disorder & Postpartum Depression
Sage Therapeutics, and Biogen announced that the U.S. Food and Drug Administration (FDA) notified the companies that the agency does not currently plan to convene an advisory committee meeting to discuss the